Claims
- 1. Prostanoids of the general formula (1) ##STR288## X is cis or trans --CH.dbd.CH--or (CH.sub.2).sub.2 --; R.sup.1 is straight or branched C.sub.1-7 alkyl bearing as a terminal substituent --COOR.sup.10 where R.sup.10 is a hydrogen atom, C.sub.1-6 alkyl or C.sub.7-10 phenalkyl;
- Y represents (i) --NR.sup.2 R.sup.3 where R.sup.2 and R.sup.3 are the same or different and are each a hydrogen atom, phenalkyl having C.sub.1-7 alkyl portion or C.sub.1-10 alkyl, both alkyls being optionally substituted by one or more substituents --OR.sup.7 (where R.sup.7 is a hydrogen atom, C.sub.1-7 alkyl, phenyl or phenyalkyl having a C.sub.1-4 alkyl portion) or --NR.sup.8 R.sup.9 (where R.sup.8 and R.sup.9 are the same or different and are each a hydrogen atom or C.sub.1-4 alkyl, or where --NR.sup.8 R.sup.9 is a saturated heterocyclic amino group as defined below for Y); any phenyl group in R.sup.2 or R.sup.3 being optionally substituted by one or more C.sub.1-4 alkyl or trifluoromethyl groups; always provided that the total numbers of carbon atoms in the group --NR.sup.2 R.sup.3 does not exceed 15;
- or (ii) a saturated heterocyclic amino group selected from the group consisting of pyrrolidino, piperdino, morpholino, piperazino, thiamorpholino, 1-dioxothiamorpholino, homomorpholino, hexamethyleneimino, piperazino substituted at the second nitrogen atom by C.sub.1-7 alkyl or phenalkyl having a C.sub.1-4 alkyl portion, and piperidino which contains in the ring the group C(OH)R.sup.6 (where R.sup.6 is a hydrogen atom, C.sub.1-7 alkyl, phenyl, or phenalkyl having a C.sub.1-4 alkyl portion) and any of said groups substituted on the ring by one or more C.sub.1-4 alkyl groups;
- R.sup.4 is a hydrogen atom, C.sub.1-6 alkyl (optionally interrupted by one or two oxygen atoms), C.sub.3-6 alkenyl, C.sub.2-4 alkanoyl, phenalkanoyl having a C.sub.2-4 alkanoyl portion, phenyl or aralkyl selected from the group consisting of benzyhydryl, naphthyl (C.sub.1-3) alkyl and phen(C.sub.1-3) alkyl and any one of said aryl groups substituted by one or more halogen, hydroxy, C.sub.1-6 alkyl C.sub.1-6 alkoxy, C.sub.1-4 hydroxyalkoxy, trifluoromethyl, cyano, phenyl, phenoxy, C.sub.5-7 cycloalkyl, phenalkoxy dimethylaminomethyl, carboxamido (--CONH.sub.2), thiocarboxamido (--CSNH.sub.2), C.sub.1-4 alkanoyl or --NR.sup.8 R.sup.9 groups as defined above);
- R.sup.5 is as defined above for R.sup.4, excluding phenyl;
- and the physiologically acceptable salts thereof; provided that when both R.sup.4 and R.sup.5 are hydrogen atoms and Y is the group --NR.sup.2 R.sup.3 in which R.sup.2 is a hydrogen atom or C.sub.1-4 alkyl, R.sup.3 is not an alkyl group which is only substituted by a hydroxy group.
- 2. Compounds as claimed in claim 1, wherein R.sup.1 is --(CH.sub.2).sub.3 COOR.sup.10 where R.sup.10 is a hydrogen atom or a C.sub.1-3 alkyl group.
- 3. Compounds as claimed in claim 1, wherein Y is pyrrolindino, piperidino, piperidino substituted by hydroxy, morpholino, thiamorpholino, 1-dioxothiamorpholino, piperazino, homomorpholino or hexamethyleneimino, or any of said groups substituted by one or more C.sub.1-4 alkyl groups.
- 4. Compounds as claimed in claim 1, wherein Y is a morpholino group or such a group substituted by one or more methyl groups.
- 5. Compounds as claimed in claim 1, wherein R.sup.4 is C.sub.1-6 alkyl, C.sub.1-6 alkyl interrupted by one or two oxygen atoms, benzyl or phenethyl, said benzyl and phenethyl groups being optionally substituted by one or more halogen atoms or C.sub.1-6 alkyl, C.sub.1-6 alkoxy, trifluoromethyl, cyano, phenyl, C.sub.5-7 cycloalkyl, amino, dialkylamino, carboxamido, thiocarboxamido, dimethylaminomethyl or formyl groups.
- 6. Compounds as claimed in claim 1, wherein R.sup.4 is other than aralkyl substituted by dimethylaminomethyl, carboxamido, thiocarboxamido or C.sub.1-4 alkanoyl.
- 7. A pharmaceutical composition comprising bronchodilating or blood platelet aggregation-inhibiting effective amount of a compound as claimed in claim 1 and one or more pharmaceutical carriers.
Priority Claims (1)
Number |
Date |
Country |
Kind |
29403/78 |
Jul 1978 |
GBX |
|
Parent Case Info
This application is a continuation of U.S. patent application Ser. No. 232,363, filed on Feb. 6, 1981, now abandoned, which was a division of U.S. patent application Ser. No. 56,416, filed July 10, 1979 now U.S. Pat. No. 4,265,891.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4182903 |
Favara et al. |
Jan 1980 |
|
4189606 |
Favara et al. |
Feb 1980 |
|
4239778 |
Venton et al. |
Dec 1980 |
|
Non-Patent Literature Citations (1)
Entry |
LeBreton et al, Proc. Natl. Acad. Sci., USA, vol. 76 (1979) pp. 4097-4101. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
56416 |
Jul 1979 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
232363 |
Feb 1981 |
|